Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.

Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD.

PLoS Genet. 2014 Feb 13;10(2):e1004135. doi: 10.1371/journal.pgen.1004135. eCollection 2014 Feb.

2.

Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.

Wang Y, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR.

Cancer Lett. 2016 Sep 28;380(1):163-73. doi: 10.1016/j.canlet.2016.05.017. Epub 2016 May 20.

PMID:
27216979
3.

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Borad MJ, Gores GJ, Roberts LR.

Curr Opin Gastroenterol. 2015 May;31(3):264-8. doi: 10.1097/MOG.0000000000000171. Review.

4.

Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.

Ang C.

J Gastroenterol Hepatol. 2015 Jul;30(7):1116-22. doi: 10.1111/jgh.12916. Review.

PMID:
25678238
5.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

6.

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.

Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, Murphy SJ, McWilliams RR, Hart SN, Halling KC, Roberts LR, Gores GJ, Couch FJ, Zhang L, Borad MJ, Kipp BR.

Hum Pathol. 2014 Aug;45(8):1630-8. doi: 10.1016/j.humpath.2014.03.014. Epub 2014 Apr 13.

PMID:
24837095
7.

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.

Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, Ojima H, Furuta K, Shimada K, Okusaka T, Kosuge T, Shibata T.

Hepatology. 2014 Apr;59(4):1427-34. doi: 10.1002/hep.26890. Epub 2014 Feb 18.

PMID:
24122810
8.

Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.

Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM.

Nat Commun. 2015 Jan 22;6:6087. doi: 10.1038/ncomms7087.

PMID:
25608663
9.

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

Zhang Z, Oyesanya RA, Campbell DJ, Almenara JA, Dewitt JL, Sirica AE.

Hepatology. 2010 Sep;52(3):975-86. doi: 10.1002/hep.23773.

PMID:
20607690
10.

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7.

PMID:
23468082
11.

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M, Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ.

Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.

12.

Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

Rizvi S, Borad MJ, Patel T, Gores GJ.

Semin Liver Dis. 2014 Nov;34(4):456-64. doi: 10.1055/s-0034-1394144. Epub 2014 Nov 4. Review.

13.

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas.

Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS.

J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52. Epub 2005 Oct 20.

PMID:
16032426
14.

Molecular aspects of cholangiocarcinoma.

Kiguchi K.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):371-9. doi: 10.1002/jhbp.66. Epub 2014 Jan 13. Review.

PMID:
24420749
15.

Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.

Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A, Nielsen ME, Maitra A, Altiok S.

Mol Cancer Ther. 2006 Jul;5(7):1895-903.

16.

Characterization of EGFR family gene aberrations in cholangiocarcinoma.

Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, Su H, Sun X, Liu Z, Zhang J, Qin X, Han B.

Oncol Rep. 2014 Aug;32(2):700-8. doi: 10.3892/or.2014.3261. Epub 2014 Jun 13.

PMID:
24927194
17.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

18.

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets.

Lee H, Wang K, Johnson A, Jones DM, Ali SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, Javle M, Ross JS.

J Clin Pathol. 2016 May;69(5):403-8. doi: 10.1136/jclinpath-2015-203394. Epub 2015 Oct 23.

PMID:
26500333
19.

Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.

Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, Shibata T.

Br J Cancer. 2009 Apr 21;100(8):1257-66. doi: 10.1038/sj.bjc.6604988. Epub 2009 Mar 24.

20.

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.

Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR.

Hum Pathol. 2013 Jul;44(7):1216-22. doi: 10.1016/j.humpath.2012.11.006. Epub 2013 Feb 4.

PMID:
23391413

Supplemental Content

Support Center